207_Combined course Presentations

First page Table of contents Previous page 905 Next page Last page

Feasibility of ”reduced dose” WBRT

The primary end points were:

a) 2-year progression-free survival (PFS)

57% in the entire population 79% in the patients who received rdWBRT

b) acute treatment-related toxicity. No evidence of neurocognitive decline within the 12-month post- rdWBRT follow-up period. One case of grade 4 neutropenia

Shah et al. JCO 2007;25

Made with